CDC Schuchat: Re Zika: CDC is working 24/7 on this most complicated emergency we've ever had. #RAforum2016
CDC Schuchat: We need more mosquito control experts .. If you want to talk about research gaps. We need more entomologists.#RAForum2016
CDC's Schuchat: There will be more emerging threats like Ebola and Zika. It's not a matter of if but when. #RAforum2016
AHRQ's Andrew Bindman: There could be 12 million diagnostic errors every year.#RAforum2016
CDC's Schuchat: With Zika, what a difference it would make to women if we had a diagnostic test for women to know if they could find out if they had Zika awhile ago? Think of how many pregnant women would be relieved. #RAforum2016
AHRQ's Bindman: We need invest more in preventing medical errors, to treat it as important an investment as we do in the leading causes of death like heart disease. #RAforum2016
USC's Amaro: income inequality is a major determiner of health. #RAforum2016
The next panel will get started at about 2:10. It's topic is "Future Forward." FDA Commissioner Robert Califf, MD, will be among the panelists.
FDA's Califf: "If we don’t have an emergency defense fund …. you’re essentially going to take away the things everyone else is counting on.”
Califf: If you do a clinical trial in a real-life population that's going to get treated and view their outcomes, you get "much better information"
FDA Commissioner Robert Califf, MD: Real-life clinical trials are becoming more feasible because of technology including electronic health records.
In the rare disease world, the first treatment out "is not the end of the game," says Emil Kakkis, MD, PhD, president of EveryLife Foundation for Rare Diseases.
We shouldn't assume "there are clinical trial police out there that are going to do the right thing," says Kweisi Mfume, a five-term member of Congress. Because of events such as the 1930s Tuskegee syphilis study, members of the African-American community may mistrust medical research. "That's not predominant today, but those things cause people to pull back," Mfume says.
Kakkis: FDA's Breakthrough Therapy program has been "enormously successful."
Califf: More than 90% of drugs in Phase I trials don't make it to market -- they may not be effective, may have unknown toxicity or may have a manufacturing problem. "When we rush (drug research), we are taking a greater risk that one of the drugs that may cause harm gets there."
Thank you for joining us today. We appreciate you being with us and hope you found today’s event informative.